Filters
Other countries
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Glioma susceptibility 1, 137800, Autosomal dominant, Somatic mutation (Glial tumor) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
NGS Panel for Dyskeratosis congenita BloodGenetics Spain | 12 | 16 |
|
Invitae United States | 59 | 16 |
|
NGS Panel for Bone Marrow failure BloodGenetics Spain | 57 | 69 |
|
Common Hereditary Cancer Screening Panel PreventionGenetics, part of Exact Sciences United States | 94 | 55 |
|
Centogene AG - the Rare Disease Company Germany | 58 | 28 |
|
Centogene AG - the Rare Disease Company Germany | 67 | 33 |
|
Centogene AG - the Rare Disease Company Germany | 114 | 68 |
|
Centogene AG - the Rare Disease Company Germany | 156 | 107 |
|
Centogene AG - the Rare Disease Company Germany | 218 | 135 |
|
Centogene AG - the Rare Disease Company Germany | 74 | 34 |
|
Centogene AG - the Rare Disease Company Germany | 12 | 1 |
|
TP53 - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany | 12 | 1 |
|
Invitae Multi-Cancer + RNA Panel Invitae United States | 143 | 63 |
|
Invitae Common Hereditary Cancers + RNA Panel Invitae United States | 114 | 47 |
|
Invitae United States | 59 | 16 |
|
Invitae Inborn Errors of Immunity and Cytopenias Panel Invitae United States | 755 | 562 |
|
Invitae Hereditary Lymphoma Panel Invitae United States | 85 | 43 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.